According to SAMHSA’s 2023 National Survey on Drug Use and Health, only 22% of people with opioid use disorder received any form of treatment in the past year. The gap between need and action is rarely about motivation. More often, it’s about not knowing what separates a program that produces lasting recovery from one that doesn’t. This guide walks you through the specific criteria that matter when choosing an opioid addiction treatment program.
What Makes an Opioid Treatment Program Actually Work
NIDA estimates that fewer than half of people who enter opioid treatment complete it, and completion rates vary dramatically based on program structure. The programs that produce the best outcomes share three non-negotiable components: medication-assisted treatment, behavioral therapy delivered with enough frequency to actually change patterns, and a treatment plan built around the individual rather than a generic protocol. Any program missing one of these three isn’t working from the evidence base. It’s working from ideology, which is a much less reliable guide.
Understanding what a well-structured treatment facility actually includes before you start making calls will save you significant time and help you ask the right questions.
Medication-Assisted Treatment Is Non-Negotiable
A 2022 study published in the New England Journal of Medicine, analyzing data from over 17,000 people with opioid use disorder, found that buprenorphine and methadone treatment reduced opioid-related mortality by approximately 50% compared to no medication. That is not a modest improvement. That is the difference between life and death, and it is the most replicated finding in addiction medicine.
Programs that decline to offer MAT on philosophical or moral grounds are not taking a conservative approach. They are ignoring the strongest evidence base in the field. Before enrolling in any program, ask two direct questions: Do you offer buprenorphine or methadone? And does MAT continue after discharge, or does the program taper patients off before they leave? A strong answer confirms both. A red flag is any program that frames medication as a crutch or suggests abstinence-only approaches are equally effective.
Behavioral Therapy Has to Be Part of the Package
A NIDA-funded trial published in the Journal of Consulting and Clinical Psychology tracked 507 people receiving MAT for opioid use disorder over 24 weeks. Participants who received cognitive behavioral therapy alongside medication had significantly higher rates of sustained abstinence at the 12-month follow-up than those receiving medication alone. The mechanism is straightforward: medication manages the neurological cravings, while therapy rebuilds the decision-making architecture that drove use in the first place. One without the other is incomplete treatment.
When evaluating any program, ask specifically how many individual therapy sessions per week are included in the standard schedule. Group sessions have value, but individual CBT with a licensed clinician is where the most durable cognitive work happens. A program offering one individual session per week is doing the minimum. A program offering three or more is serious about outcomes.
The Difference Between Residential and Outpatient Care
The American Society of Addiction Medicine’s placement criteria offer a clear framework for this decision, and the research supports their logic. For people with moderate to severe opioid use disorder, residential care consistently outperforms outpatient when any of the following conditions are present: an unstable or actively using home environment, a co-occurring mental health condition that needs daily clinical oversight, or a prior failed attempt at outpatient treatment.
Structured outpatient programs are appropriate for people with strong, recovery-supportive social networks, lower medical complexity, and stable housing. If you’re researching options for yourself or a family member and any of those outpatient prerequisites are missing, residential is the right level of care, not a more intensive version of outpatient. If you’re unsure whether a residential program matches the level of structure that’s actually needed, the ASAM criteria give you an objective checklist to apply before making that call.
How to Evaluate a Program’s Credentials and Outcomes
A 2022 Government Accountability Office report on substance use disorder treatment found substantial variation in care quality across licensed facilities, with licensure alone insufficient to guarantee evidence-based practice. State licensure is the floor, not the ceiling. The accreditation bodies that signal genuine quality are the Joint Commission (JCAHO) and CARF International. Both require programs to demonstrate specific clinical standards, outcome tracking, and regular external review. A program without at least one of these accreditations deserves much more scrutiny before you commit.
Beyond accreditation, ask any program for their 12-month treatment completion rate and their 12-month sobriety rate for graduates. The national average completion rate for residential opioid treatment hovers around 40 to 50%. Any program unwilling to share these numbers is telling you something. A program with completion rates above 60% and documented outcome tracking is operating with accountability.
Questions to Ask Before You Commit
This is due diligence, not suspicion. Any reputable program expects these questions and welcomes them.
Start with MAT availability and coverage: is medication-assisted treatment offered, and does your insurance cover it at this facility? Follow with the staff-to-patient ratio, because anything above 1:6 in a residential setting is a quality signal. Then ask how co-occurring mental health conditions are handled. The answer you want is integrated dual-diagnosis care with licensed mental health clinicians on-site. The answer that should concern you is a referral to an outside provider, because that structure creates gaps that drive relapse.
Finally, ask what aftercare planning looks like at discharge. A strong program has a specific, individualized plan in place weeks before a client leaves, not a list of community resources handed over on the last day.
Co-Occurring Mental Health Conditions Change the Equation
A 2021 analysis in JAMA Psychiatry found that among people with opioid use disorder, roughly 43% met criteria for a co-occurring depressive disorder and 30% met criteria for PTSD. These aren’t edge cases. In any treatment population drawn from people with significant trauma histories or chronic pain, co-occurring conditions are the norm, not the exception.
Programs that treat addiction and mental health in separate silos produce measurably worse outcomes. When the PTSD or depression goes unaddressed, it remains the most powerful driver of relapse after discharge. Before enrolling, confirm whether licensed mental health clinicians are employed on-site and whether therapies specifically designed for trauma, such as EMDR or Accelerated Resolution Therapy, are part of the standard clinical offering. If a program treats addiction separately from the mental health conditions sustaining it, the treatment is incomplete by design. For people carrying significant trauma, a prescription drug rehab that integrates trauma-informed modalities isn’t a premium feature. It’s a clinical requirement.
What Insurance Covers and How to Verify It Before You Go
The Mental Health Parity and Addiction Equity Act legally requires insurers to cover substance use disorder treatment at the same level as medical care. A 2023 Milliman analysis commissioned by the Addiction Policy Forum found that despite this requirement, insurers deny residential addiction treatment claims at rates substantially higher than comparable medical claims, often citing “medical necessity” determinations that apply standards not used in any other area of care.
Knowing this going in changes how you approach the call with your insurer. The single most useful question to ask the benefits line is this: does this specific program require prior authorization, and what clinical documentation triggers approval? Getting that answer in writing, or at minimum documented with a call reference number, gives you the foundation to appeal if a claim is denied. The distinction between in-network and out-of-network coverage matters significantly for residential care, where cost differences can run into thousands of dollars per week. Verify the facility’s network status directly with your insurer, not just with the facility’s admissions team. If you’re still figuring out where to start this process, understanding how insurance intersects with rehab placement can clarify what to prioritize before you pick up the phone.
Making the Call That Starts Everything
Identify two or three programs that meet every criterion covered here: Joint Commission or CARF accredited, MAT-inclusive with post-discharge continuation, dual-diagnosis capable with on-site mental health clinicians, and verified in-network with your insurance. Then call each one and ask the single most diagnostic question first: is medication-assisted treatment offered, and does it continue after discharge?
That call takes thirty minutes. It is the concrete move that separates people who enter treatment from people who keep researching it.